Evidence map›Paper›PMID 31345265›Full record

ArticleParasites & vectors2019

A combination of antibodies against Bm86 and Subolesin inhibits engorgement of Rhipicephalus australis (formerly Rhipicephalus microplus) larvae in vitro.

Jos J A Trentelman, Hendry Teunissen, Jos A G M Kleuskens, Jos van de Crommert, José de la Fuente, Joppe W R Hovius, Theo P M Schetters

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Recent Advances in Tick Antigen Discovery and Anti-Tick Vaccine Development.International journal of molecular sciences · 2023
    Review
  8. Tick Vaccines and Concealed versus Exposed Antigens.Pathogens (Basel, Switzerland) · 2023
    Article
  9. Repellency and toxicity of a COExperimental & applied acarology · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Jos J A TrentelmanCenter for Experimental and Molecular Medicine, Amsterdam Infection & Immunity, Amsterdam UMC, Univ of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands. j.j.trentelman@amsterdamumc.nl.ORCID http://orcid.org/0000-0001-5393-9706
Hendry TeunissenMérieux NutriSciences, Pascalstraat 25, 6716 AZ, Ede, The Netherlands.
Jos A G M KleuskensMSD Animal Health, Wim de Körverstraat 35, 5830 AA, Boxmeer, The Netherlands.
Jos van de CrommertAduro Biotech Europe, Kloosterstraat 9, 1101 RX, Boxmeer, The Netherlands.
José de la FuenteSaBio. Instituto de Investigación en Recursos Cinegéticos IREC (CSIC-UCLM-JCCM), 13005, Ciudad Real, Spain.
Joppe W R HoviusCenter for Experimental and Molecular Medicine, Amsterdam Infection & Immunity, Amsterdam UMC, Univ of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Theo P M SchettersProtActivity, Sering 36, 5432 DD, Cuijk, The Netherlands.
Achmea (Netherlands) · NLAmsterdam Neuroscience · NLAmsterdam University Medical Centers · NLOklahoma State University · USOnderstepoort Veterinary Academic Hospital · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRhipicephalus microplus is a hard tick species that has a high impact on cattle health and production in tropical and subtropical regions. Recently, ribosomal DNA and morphological analysis resulted in the reinstatement of R. australis as a separate species from R. microplus. Both feed on cattle and can transmit bovine pathogens such as Anaplasma and Babesia species. The current treatment with acaricides is becoming increasingly less effective due to the emergence of resistant tick strains. A promising alternative can be found in the form of anti-tick vaccines. The available commercial vaccines can be used to control tick infestation, but the lack of a knockdown effect (> 90% reduction in tick numbers as seen with effective acaricides) hampers its widespread use, hence higher efficacious vaccines are needed. Instead of searching for new protective antigens, we investigated the efficacy of vaccines that contain more than one (partially) protective antigen. For screening vaccine formulations, a previously developed in vitro feeding assay was used in which R. australis larvae are fed sera that were raised against the candidate vaccine antigens. In the present study, the efficacy of the Bm86 midgut antigen and the cytosolic Subolesin (SUB) antigen were evaluated in vitro.

resultsAntiserum against recombinant Bm86 (rBm86) partially inhibited larval engorgement, whereas antiserum against recombinant SUB (rSUB) did not have any effect on feeding of larvae. Importantly, when larvae were fed a combination of antiserum against rBm86 and rSUB, a synergistic effect on significantly reducing larval infestations was found. Immunohistochemical analysis revealed that the rBm86 antiserum reacted with gut epithelium of R. australis larvae, whereas the antiserum against rSUB stained salivary glands and rectal sac epithelium.

conclusionsCombining anti-Bm86 and anti-subolesin antibodies synergistically reduced R. australis larval feeding in vitro. Rhipicephalus australis is a one host tick, meaning that the larvae develop to nymphs and subsequently adults on the same host. Hence, this protective effect could be even more pronounced when larvae are used for infestation of vaccinated cattle, as the antibodies could then affect all three developmental stages. This will be tested in future in vivo experiments.

Indexed as

AnimalsAntibodiesAntigensArthropod ProteinsCattleFemaleImmune SeraLarvaMembrane GlycoproteinsRecombinant ProteinsRhipicephalusVaccinesAntibodiesAntigensArthropod ProteinsImmune SeraMembrane GlycoproteinsRecombinant Proteinssubolesin, tickVaccinesArtificial tick feedingBm86In vitro screeningR. australisR. microplusSubolesinVaccine

Identifiers

PMID31345265
PMCPMC6657053
OpenAlexW2964223914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.